Exact Sciences Corporation

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-11 pm EST			5-day change	1st Jan Change
103.43 ^USD	+0.08%		+1.13%	+1.84%

Feb. 03	Exact Sciences Corp. Announces A Significant Milestone for Its Oncotype DX Breast Recurrence Score Test	CI
Jan. 30	The Fed's Next Chair: Reformist, Realist, or Rubber Stamp?

Top Midday Gainers

Published on 11/20/2025 at 03:28 pm EST

MT Newswires

Latest news about Exact Sciences Corporation

Feb. 03	Exact Sciences Corp. Announces A Significant Milestone for Its Oncotype DX Breast Recurrence Score Test	CI
Jan. 30	The Fed's Next Chair: Reformist, Realist, or Rubber Stamp?
Jan. 30	German cartel office approved planned acquisition of Exact Sciences by Abbott	RE
Jan. 22	Abbott Laboratories Raised Prices, Prompting Sales Slump -- Update	DJ
Jan. 22	Abbott Laboratories 4Q Sales Grow, Outlook Underwhelms	DJ
Jan. 21	When America Starts to Feel Like a Risky Asset
Jan. 20	Greenland, Tariffs, and the Quiet Revolt of the Bond Market
Jan. 20	Mizuho Downgrades Exact Sciences to Neutral From Outperform, Adjusts Price Target to $105 From $85	MT
Jan. 20	Analyst recommendations: Intel, Philip Morris, Duolingo, Netflix, SanDisk…
Jan. 12	Mdxhealth reports preliminary fourth quarter and full year 2025 revenues, issues 2026 revenue guidance, and amends earnout terms with Exact Sciences	RE
Jan. 08	Quanterix Names Everett Cunningham President and CEO	MT
Jan. 08	Quanterix Names Everett Cunningham President and CEO	MT
Dec. 30	Alert from law firm on Exact Sciences-Abbott deal withdrawn	RE
Dec. 11	Exact Sciences Corp. Announces the First Clinical Study Results from Its Oncodetect Molecular Resistant Disease Test in Early Triple-Negative Breast Cancer	CI
Dec. 01	Stifel Downgrades Exact Sciences to Hold From Buy, Adjusts Price Target to $105 From $80	MT
Nov. 26	Pacific Edge Limited Announces the Appointment of James Vaughn, R.Ph. into the New Role of Chief Commercial Officer, Effective on 1 December 2025	CI
Nov. 25	Wall Street Continues to Shift
Nov. 25	Canaccord Genuity Downgrades Exact Sciences to Hold From Buy, Adjusts PT to $105 From $85	MT
Nov. 25	TD Cowen Downgrades Exact Sciences to Hold From Buy, Adjusts PT to $105 From $90	MT
Nov. 25	Analyst recommendations: Accenture, Dell, Estee Lauder, Applovin, Dupont de Nemours…
Nov. 24	Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence At 2025 San Antonio Breast Cancer Symposium	CI
Nov. 24	UBS Adjusts Price Target on Exact Sciences to $105 From $80, Maintains Neutral Rating	MT
Nov. 24	Piper Sandler Downgrades Exact Sciences to Neutral From Overweight, Adjusts Price Target to $105 From $80	MT
Nov. 24	Jefferies Downgrades Exact Sciences to Hold From Buy, Adjusts Price Target to $105 From $90	MT
Nov. 24	Benchmark Downgrades Exact Sciences to Hold From Buy	MT

Chart Exact Sciences Corporation

Duration

Period

EXAS: Dynamic Chart

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Companyâ€™s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Companyâ€™s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patientâ€™s breast tumor tissue.

Employees

6,950

Sector

Biotechnology & Medical Research

Calendar

Feb. 23 - Q4 2025 Earnings Release (Projected)

More about the company